Abscisic acid ((S)-(+)-Abscisic acid) 是一种口服有效的植物激素,存在于水果和蔬菜中,也是一种内源性的哺乳动物激素。Abscisic acid 是一种生长抑制剂,可以调节植物生长发育。Abscisic acid 抑制质子泵 (H+-ATPase),并导致 Ca2+依赖性的质膜去极化。Abscisic acid 是 LANCL2 的天然配体,是一种有效的胰岛素敏感化合物,具有用于糖尿病前期,2 型糖尿病和代谢综合征研究的潜力。
生物活性 | Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibitsproton pump(H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome[1][2]. |
IC50& Target[1] | Microbial Metabolite | Human Endogenous Metabolite |
|
体外研究 (In Vitro) | In Arabidopsis cell cultures, Abscisic acid ((S)-(+)-Abscisic acid; 10 μM) simultaneously induces rapid alkalinization of the medium and plasma membrane depolarization[1]. Abscisic acid (10 μM) increases Ca2+in cytosol of Arabidopsis cell suspension. Abscisic acid does not inhibit proton pumping directly but through an increase in cytosolic Ca2+[1]. Lanthionine synthetase C-like 2 (LANCL2) is the natural receptor for Abscisic acid. Abscisic acid, both at the organism levels and in specific muscle cells ex vivo, increases both glucose and fatty acid metabolism in the mitochondria, increases glycogen synthesis, activates PI3K independently of insulin and promotes GLUT4 translocation to the cell membrane[2].
|
体内研究 (In Vivo) | Abscisic acid (orally; 0.125 μg/kg/day; for 12 weeks) improves glycemic control[2]. Abscisic acid (orally; 0.125 μg/kg/day; for 12 weeks) results in significantly lower levels of TNF, MCP-1 and IL-6 in the DIO model. Abscisic acid increases metabolic activity in skeletal muscle[2].
Animal Model: | Diet-induced obesity (DIO) mice at 4 weeks of age[2] | Dosage: | 0.125 μg/kg | Administration: | Orally; daily; for 12 weeks | Result: | Improved glycemic control in a diet-induced model of obesity |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(378.33 mM;Need ultrasonic) 配制储备液 1 mM | 3.7833 mL | 18.9165 mL | 37.8329 mL | 5 mM | 0.7567 mL | 3.7833 mL | 7.5666 mL | 10 mM | 0.3783 mL | 1.8916 mL | 3.7833 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 6.25 mg/mL (23.65 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (23.65 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 6.25 mg/mL (23.65 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (23.65 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 6.25 mg/mL (23.65 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (23.65 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|